Physician
Southeastern Pediatrics, SC
Southeastern Pediatrics, SC was paid $1.79M by Medicaid between Jan 2018 and Dec 2024, across 76 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoSOUTHEASTERN PEDIATRICS, SC
WAUWATOSA, WI 53226
WAUWATOSA, WI 53226
33aNPI1154765410assigned 04/17/2013
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$1.79M
24GClaims119,512
24DCodes billed76
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Wisconsin
Rank by total paid#1 of 6
Median peer was paid$28K
This provider vs. median63×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,767 | $282K | |
| 2019 | 19,157 | $275K | |
| 2020 | 19,033 | $280K | |
| 2021 | 18,487 | $288K | |
| 2022 | 19,138 | $259K | |
| 2023 | 16,336 | $224K | |
| 2024incomplete | 9,594 | $187K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 14,478 | 10,846 | $414K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 22% | 8,936 | 7,039 | $401K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.9% | 1,758 | 1,522 | $88K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.0% | 1,430 | 1,221 | $71K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.6% | 1,262 | 1,089 | $65K |
| D1208 | Topical application of fluoride, excluding varnish | 3.5% | 5,961 | 4,968 | $63K |
| 80061 | Lipid panel | 3.1% | 5,275 | 4,217 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 7,079 | 5,713 | $46K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.4% | 791 | 704 | $43K |
| 3008F | 2.3% | 5,639 | 4,664 | $42K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.3% | 5,091 | 3,982 | $41K |
| 99173 | 2.1% | 2,949 | 2,448 | $37K |
64 more codes
| 87631 | 2.1% | 421 | $37K | |
| 99000 | 1.7% | 10,924 | $31K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.7% | 1,029 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 844 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.4% | 1,204 | $26K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 1,210 | $25K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.4% | 1,120 | $24K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 3,258 | $24K |
| D0140 | Limited oral evaluation - problem focused | 1.3% | 5,810 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 247 | $20K |
| 83655 | <1% | 1,749 | $17K | |
| 82947 | <1% | 5,289 | $17K | |
| 99188 | <1% | 1,203 | $11K | |
| 81003 | <1% | 6,785 | $11K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 471 | $10K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 184 | $9K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 183 | $9K |
| 36416 | <1% | 4,347 | $8K | |
| 94664 | <1% | 458 | $7K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 93 | $6K |
| 99050 | <1% | 396 | $6K | |
| 90656 | <1% | 1,199 | $5K | |
| 0001A | <1% | 162 | $5K | |
| 0002A | <1% | 117 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 405 | $4K |
| 90686 | <1% | 411 | $3K | |
| 90670 | <1% | 677 | $3K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 40 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 85 | $2K |
| 81025 | <1% | 325 | $2K | |
| 90698 | <1% | 317 | $1K | |
| 90651 | <1% | 271 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 109 | $1K |
| 90734 | <1% | 339 | $1K | |
| 94010 | <1% | 33 | $1K | |
| 90621 | <1% | 212 | $1K | |
| 90715 | <1% | 173 | $1K | |
| 0071A | <1% | 31 | $850.00 | |
| 90619 | <1% | 92 | $834.60 | |
| 90677 | <1% | 75 | $771.65 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 55 | $762.97 |
| 99384 | <1% | 22 | $685.42 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 28 | $684.00 |
| 90661 | <1% | 46 | $591.78 | |
| 90633 | <1% | 150 | $524.63 | |
| 0072A | <1% | 17 | $514.40 | |
| 90744 | <1% | 150 | $508.83 | |
| 0003A | <1% | 13 | $502.95 | |
| 99442 | <1% | 48 | $453.60 | |
| 90655 | <1% | 98 | $364.69 | |
| 94760 | <1% | 388 | $297.76 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 196 | $262.27 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 645 | $227.54 |
| 99443 | <1% | 15 | $99.82 | |
| 90681 | <1% | 17 | $66.52 | |
| 81002 | <1% | 16 | $58.41 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 649 | $38.73 |
| 90710 | <1% | 14 | $38.01 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,905 | $25.38 |
| 91300 | <1% | 405 | $0.09 | |
| 91307 | 0% | 18 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 40 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 469 | $0.00 |
| 90461 | 0% | 161 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIOGA, RATIDZAI (PRESIDENT)